#United States #Burlington #Multiomics #Azenta Life Sciences #Trey Martin

Leadership Transition at Azenta Life Sciences

Azenta Life Sciences, a leading provider in the life sciences sector, has recently made a significant leadership change aimed at bolstering its strategic direction in gene synthesis and multiomics initiatives. Effective April 6, 2026, Trey Martin will assume the role of President of Azenta's Multiomics business. This decision follows a comprehensive review of the company’s future and growth potential, outlined during their Investor Day event in December 2025.

Focus on Multiomics Growth

In his new position, Mr. Martin will oversee the Multiomics division and will report directly to John Marotta, the President and CEO of Azenta. The company's goals are clear: they aim to accelerate the execution of their long-term Multiomics strategy, which is characterized by global synthesis capabilities, operational excellence, and sustainable growth across integrated platforms. These objectives are intended to modernize and streamline operations that support a wider adoption and enhanced performance in the market.

John Marotta expressed confidence in Martin's capability to lead this significant initiative: "Trey is exceptionally well-positioned to lead the next phase of our Multiomics strategy," he stated. With over three decades of experience in life sciences operations and a proven track record in scaling complex businesses, Martin is expected to play a pivotal role in advancing Azenta's ambitions further.

A New Chapter for Multiomics

Ginger Zhou, who has been at the helm of the Multiomics division, will step down from her role but will continue to provide advisory support until November 2026. Her transition is designed to ensure that there is continuity as the business shifts into this new phase under Martin’s leadership. Marotta acknowledged her contributions in establishing a solid foundation for the Multiomics business, laying the groundwork for what comes next.

Trey Martin comes to Azenta from his previous role as CEO of Maravai Life Sciences, where he successfully drove significant operational transformations. Before that, he held leadership roles at Danaher Corporation, including overseeing their Genomic Medicines segment and leading Integrated DNA Technologies. His extensive experience in the life sciences arena equips him uniquely to drive growth strategies and implement changes that are beneficial for the organization.

Vision for Future Success

In a statement, Martin expressed his enthusiasm about joining Azenta: "The business has a strong foundation with deep global expertise and an important role enabling scientists from foundational research to the clinic. I see tremendous opportunities to further differentiate and scale Azenta's unique genomics services and synthesis capabilities to meet the evolving needs of our global customers."

This leadership transition signifies a critical moment for Azenta as they gear up to execute their strategic priorities, enhance operational excellence, and work towards delivering sustainable, profitable growth. The importance of effective leadership during this transformative era cannot be overstated, as the firm navigates the complexities of life sciences innovation in an ever-evolving industry landscape.

About Azenta Life Sciences

Based in Burlington, Massachusetts, Azenta Inc. (Nasdaq: AZTA) is recognized globally for providing crucial life science solutions that enable various organizations to expedite the delivery of impactful breakthroughs and therapies to market. Their range of services includes reliable cold-chain sample management solutions and multiomics offerings that cater to drug development and clinical research.

Azenta supports its operations across North America, Europe, and Asia, leveraging top-tier brands such as GENEWIZ and FluidX, contributing to the ongoing advancements in healthcare and technology. As they continue to enhance their capabilities under Martin’s leadership, the firm is poised to solidify its position in the life sciences sector and beyond, further driving innovation and market responsiveness.